

Atty. Docket No. P65678US0  
Serial No. 09/582,328

wherein R<sub>1</sub> is NH<sub>2</sub>, an amino acid, or a peptide with up to 1000 amino acids, and R<sub>2</sub> is COOH, CONH<sub>2</sub>, an amino acid, or a peptide with up to 1000 amino acids.

REMARKS

Claims 41-60 are pending.

The specification and claims (claim 45) are amended hereby in order to insert adjacent to sequences, therein, the corresponding sequence identifier found in the Sequence Listing.

The Notice to Comply mistakenly indicates that the sequences recited in claim 45 are not found in the paper copy of the Sequence Listing. On the contrary, the sequences recited in claim 45 correspond to SEQ. ID. NOS: 30-41 in the paper copy of the Sequence Listing.


As such, Applicants need not provide the items indicated on the Notice to Comply, i.e., Applicants need not provide a substitute CRF, a substitute paper copy of the Sequence Listing, or a statement required under 37 CFR 1.821.

Atty. Docket No. P65678US0  
Serial No. 09/582,328

Favorable action is requested.

Respectfully submitted,

JACOBSON·HOLMAN PLLC

  
\_\_\_\_\_  
William E. Player  
Reg. No. 31,409

400 Seventh Street, N.W.  
Washington, D.C. 20004  
Tel. No.: 202-638-6666  
Atty. Dkt. No. P65678US0  
Date: October 30, 2002  
WEP/rdt

R:\rthomas\2002\OCTOBER\P65678amd.wpd

*Marked up Version of Amendments*

IN THE SPECIFICATION

Replace paragraph that bridges pages 3 and 4 of specification with:

-- R<sub>1</sub>-C-HEFQAFMKNGKLF-C-PQDKFFQSLDGIMFINK-C-AT-C-R<sub>2</sub> (SEQ ID NO: 30)  
R<sub>1</sub>-C-DDFKKGERDGDFI-C-PDYYEAVCGTDGKYDNR-C-AL-C-R<sub>2</sub> (SEQ ID NO: 31)  
R<sub>1</sub>-C-SAFRPFVRNGRLG-C-TRENDPVLGPDGKTHGNK-C-AM-C-R<sub>2</sub> (SEQ ID NO: 32)  
R<sub>1</sub>-C-KEYEKQVRNGRLF-C-TRESDPVRGPDRGMHGNK-C-AL-C-R<sub>2</sub> (SEQ ID NO: 33)  
R<sub>1</sub>-C-SQYQNQAKNGILF-C-TRENDPIRGPDGKMHGNL-C-SM-C-R<sub>2</sub> (SEQ ID NO: 34)  
R<sub>1</sub>-C-NEYRKLVNGKLA-C-TRENDPIQGPDGKVHGNT-C-SM-C-R<sub>2</sub> (SEQ ID NO: 35)  
R<sub>1</sub>-C-SEYRKSRKNGRLF-C-TRENDPIQGPDGKMHGNT-C-SM-C-R<sub>2</sub> (SEQ ID NO: 36)  
R<sub>1</sub>-C-SEFRDQVRNGTLI-C-TREHNPVRGPDRGMHGNK-C-AM-C-R<sub>2</sub> (SEQ ID NO: 37)  
R<sub>1</sub>-C-SEYRHYVRNGRLP-C-TRENDPIEGLDGKIHGNT-C-SM-C-R<sub>2</sub> (SEQ ID NO: 38)  
R<sub>1</sub>-C-DEFRPLLQNGKLF-C-TRENDPVRGPDRGMHGNK-C-AM-C-R<sub>2</sub> (SEQ ID NO: 39)  
R<sub>1</sub>-C-AEYREQMKNGRLS-C-TRESDPVRDADGKSYNNQ-C-TM-C-R<sub>2</sub> (SEQ ID NO: 40)  
R<sub>1</sub>-C-DEFRSQMKNGKLI-C-TRESDPVRGPDRGMHGNK-C-TM-C-R<sub>2</sub> (SEQ ID NO: 41), --

IN THE CLAIMS

Rewrite the following claim.

45 (amended). The serine protease inhibitor according to claim 41, having one of the following formulas:

- R<sub>1</sub>-C-HEFQAFMKNGKLF-C-PQDKKFFQSLDGIMFINK-C-AT-C-R<sub>2</sub> (SEQ ID NO: 30)
- R<sub>1</sub>-C-DDFKKGERDGDFI-C-PDYYEAVCGTDGKYDNR-C-AL-C-R<sub>2</sub> (SEQ ID NO: 31)
- R<sub>1</sub>-C-SAFRPFVRNGRLG-C-TRENDPVLGPDGKTHGNK-C-AM-C-R<sub>2</sub> (SEQ ID NO: 32)
- R<sub>1</sub>-C-KEYEKQVRNGRLF-C-TRESDPVRGPDGKMHGNK-C-AL-C-R<sub>2</sub> (SEQ ID NO: 33)
- R<sub>1</sub>-C-SQYQNQAKNGILF-C-TRENDPIRGPDGKMHGNL-C-SM-C-R<sub>2</sub> (SEQ ID NO: 34)
- R<sub>1</sub>-C-NEYRKLVNGKLA-C-TRENDPIQGPDGKVHGNT-C-SM-C-R<sub>2</sub> (SEQ ID NO: 35)
- R<sub>1</sub>-C-SEYRKSRKNGRLF-C-TRENDPIQGPDGKMHGNNT-C-SM-C-R<sub>2</sub> (SEQ ID NO: 36)
- R<sub>1</sub>-C-SEFRDQVRNGTLI-C-TREHNPVRGPDGKMHGNK-C-AM-C-R<sub>2</sub> (SEQ ID NO: 37)
- R<sub>1</sub>-C-SEYRHYVRNGRLP-C-TRENDPIEGLDGKIHGNT-C-SM-C-R<sub>2</sub> (SEQ ID NO: 38)
- R<sub>1</sub>-C-DEFRRLLQNGKLF-C-TRENDPVRGPDGKTHGNK-C-AM-C-R<sub>2</sub> (SEQ ID NO: 39)
- R<sub>1</sub>-C-AEYREQMKNGRLS-C-TRESDPVRDADGKSNNQ-C-TM-C-R<sub>2</sub> (SEQ ID NO: 40)
- R<sub>1</sub>-C-DEFRSQMKNGKLI-C-TRESDPVRGPDGKTHGNK-C-TM-C-R<sub>2</sub> (SEQ ID NO: 41),

wherein R<sub>1</sub> is NH<sub>2</sub>, an amino acid, or a peptide with up to 1000 amino acids, and R<sub>2</sub> is COOH, CONH<sub>2</sub>, an amino acid, or a peptide with up to 1000 amino acids.